Slides
Page 1
TelyRx Investor Presentation | August 2026 TelyRx : Healthcare Reimagined Prescriptions on Demand TSX : TELY | OTCQX : TELYF
Page 2
2 D I S C L A I M E R Important Disclosures & Forward-Looking Statements Thispres entationisforinformationalpurposesonlyanddoesnotconstituteanoffertosellorasolicitationofanoffertobuyanysecuritiesof TelyRxinanyjuris dictionwhereitwouldbeunlawfultomakesuchanofferorsolicitation.Theinformationcontainedinthispres entationhas beenpreparedas of August10, 2026, andis providedas at thedatehereofandis subjectto changewithoutnotice. Exceptwhere otherwiseindicated.,inthispresentation,referencesto“$”and“dollars”aretoUnitedStatesdollars. FORWARD-LOOKINGSTATEMENTS Thispres entationcontains“forward-lookinginformation”and“forward-lookingstatements”withinth emeaningof applicableCanadian securitieslaws. Suchstatementsinclude,butarenotlimitedto,statementsregardingTelyRx’sbus inessoperationsandabilitytoprovide timelyaccesstomedication,futurerevenueandEBITD Agrowthandotherfinancialperformance,thepredictabilityoffinancialmetrics,the pac eofscalingofourplat form,ourstructuralpositioningadvantag e,thesizeandpotentialgrowthofourtargetmarket,changingcustomer preferences,thereductioninthenumberofbrickandmortarpharmac ies,thegrowthofourcustomerbas eandretentionofcustomers,the stabilityofourcustomeracquis itioncost,thenatureofourcompetitors,thepotentialbenefitsoftheStarkL awcompetitivemoatenduring, growthinwebsitetraffic,thepotentialadvantag esofinhousemarketinggrowth,ouruseofproceeds,growthopportunities,marketoutlook andcustomereconomics. Thispres entationincludesinformation ,statements,beliefsandopinionswhichareforward-lookingpurs uanttoUnitedStatesSecuritieslaws, andwhichreflectcurrentestimates,expectationsandprojectionsaboutfutureeventsreferredtohereinandwhichconstitute“forward- lookingstatements”(withinthemeaningofSection27AoftheSec uritiesActof1933,asamendedandSection21EoftheSecuritiesExchange Actof1934,asamended). Thes estatementsareident ifiedbytermssuchas“antic ipat es,”“believes,”“expects,”“intends,”“plans,”“forecast s,”“may,”“will,”“could,” “would,”and similarexpressions. Forward-lookingstatementsare basedon management’scurrentexpectationsand assumptions, includinggeneraleconomicandmarketconditions,TelyRx’sabilitytoexecuteitsstrategy,theextentandn atureofitscompetitionandthe ben efitsof theStarkLawcompetitivemo aten during,customerpreferen ces,thestabilityof ourcustomeracquisitioncostandrepeat customerrate,theCanadian/USdollarexchangerateandtheevolvingregulatorylan dscape. Whiletheseass umptionsarebelievedtobe reasonable,actualresultsmaydiffermateriallyduetoknownandunknownrisksincludingthosesetoutbelowunder“RiskFactors”. Any forward-lookinginformationspeaksonlyasofthedateonwhichitismade,an d,exceptasrequiredbylaw,theCo mpanydo esnotundertake anyobligationtoupdateorreviseanyforward-lookinginformation,whetherasaresultofnewinformation,futureevents,orotherwise.New factorsemergefromtimetotime,anditisnotpossiblefortheCompanytopredictallsuchfactors. NON-IFRSMEASURES Thispresent at ionusescertainnon-IFRSmeas uresof theCompany. Theterm“EB ITDA”andA djust edEarning sBeforeInt eres t,Taxes, Deprec iationandAmortization(“AdjustedEBITD A”)and FreeCashFlow(“FCF”)donothaveanystandardizedmeaningprescribedwith in Intern ationalFinancialReportingStandards(“IFRS”)and thereforemay not be comparableto similarmeas urespresentedby other companies. WebelievethatEBITD AandAdjustedEBITDA,whentakento getherwiththecorrespondingIFRSfinancialmeasures,provide meaningfulsupplementalinformationregardingourperformancebyexcludingcertainitemsthatmaynotbeindicativeofourbusin ess, resultsofoperations,oroutlook. WeconsiderEB ITDA,Adjus tedEB ITDAandFCFtobeimportantmeas uresbecauseth eyhelpillustrate underlyingtrendsinourbusinessandourhistoricaloperatingperformanceona moreconsistentbasis.WebelievethattheuseofEBITD A, AdjustedEB ITDAandFCFishelpfultoourinvestorsastheyareusedbymanagementinassessingthehealthofourbus iness,ouroperating performance,andourliquidity. However,non-IFRSfinancialinformationispresentedforsupplementalinformationalpurposesonly,haslimitationsasananalyticaltool,andshould notbeconsideredinisolationorasasubstituteforfinancialinformationpresentedinaccordancewithIFRS.Inaddition,othercompanies,including companiesinourindustry,maycalculatesimilarly-titlednon-IFRSfinancialmeas uresorratiosdifferentlyormayuseotherfinancialmeasuresor ratiosto evaluatetheirperformance,all of whichcouldreducethe usefulnessof non-IFRSfinancialmeasuresas toolsfor comparison. ReconciliationsareprovidedbelowtothemostdirectlycomparablefinancialmeasuresstatedinaccordancewithIFRS.Investorsareencourag edto reviewourIFRSfinancialmeasuresandnottorelyonanysinglefinancialmeasuretoevaluateourbusiness. EBITDAandAdjustedEBITDA EB ITDAiscalc ulatedh ereinasnetearningsfromoperationsbeforeinterestexpense,taxexpense,depreciation,andamortization.Areconciliationof EB ITDAtonetincomean dareconciliationisavailableuponrequest.TheCo mpanypresentstheEB ITDAonaconsistentbasisfro mperiodtoperio d andgainsandlossesfromonetimenon-recurringeventsareeliminated. WedefineAdjustedEBITD Aasnetincome/ (loss)adjustedforinterest expense,depreciationandamortization,stock-basedcompensation,transactionexpensesandgain/ (loss)fromdiscontinuedoperations,and incometax(benefit)/provision,asapplicable. SomeofthelimitationsofAdjus tedEBITD Ainclude:(i)AdjustedEBITD Adoesnotproperlyreflectcapital commitmentstobepaidinthefuture,and(ii)althoughdepreciationandamortizationarenon-cashcharges,theunderlyingassetsmayneedtobe replacedandAdjustedEBITD Adoesnotreflectthesec apitalexpenditures. InevaluatingAdjustedEB ITDA,youshouldbeawarethatinthefuturewe willincurexpensessimilartotheadjustmentsinthispresentation.Ourpresen tationofAdjustedEB ITDAshouldnotbeconstruedasaninferencethat ourfutureresultswillbeun affectedbytheseexpens esoranyunusualornon-recurringitems. Wecompensatefortheselimitationsbyproviding specificinformationreg ardingtheIFR SitemsexcludedfromAdjus tedEBITDA. Whenevaluatingourperformance,youshouldconsiderAdjusted EBITDAinadditionto,andnotasasubstitutefor,otherfinancialperformancemeasures,includingournetincome(loss)andotherIFRSresults. FreeCashFlow FreeCashFlowisakeyperformancemeasurethattheCompanyusestoassessliquidity.Becaus eFreeCashFlowfacilitatesinternalcomparisonsof theCompany’shistoricalliquidityona moreconsistentbasis,theCompanyusesthismeasureforbusinessplann ingpurposes.FreeCashFlowis definedasnetcashprovidedby(us edin)operatingactivities,lesspurchasesofproperty,equipment,andintangibleassetsandinvestmentininternal- usesoftwareininvestingactivities. Pleas eseetheinformationsetoutundertheheading“Non-IFRSFinancialMeas ures”intheManagementDiscussion&AnalysisoftheCompanyfor theperiodendedJun e30,2026includinginparticularth ereconciliationofAdjustedEBITD Awithnetlossandtherec onciliationofFreeCashFlowwith Netcashprovidedby(usedin)operatingactivities,whichinformationisincorporatedhereinbyreference. SECURITIESLAWSCOMPLIANCE Thispresent ationisnotaprospectusoranadvert isementandisbeingprovidedforinformationpurposesonlyanddoesnotconstituteorformpartof, andshouldnotbeconstruedas,anofferorinvitationtoselloranysolicitationofanyoffertopurchaseorsubscribeforanysecuritiesofTelyRxin Canada,theUnitedStatesoranyotherjuris dictionwhereitisnotlawfultodoso.Neitherthispresentation,noranypartofit,noranythingcontainedor referredtoinit,northefactofitsdistribution,shouldformthebasisoforbereliedoninconnectionwithoractasaninducementinrelationtoadecis ion topurchaseorsubscribefororenterintoanycontractormakeanyothercommitmentwhatsoeverinrelationtoanysecuritiesofTelyRx. This presentationdoesnotconstitutearecommendationregardinganysecuritiesoraninvestmenttherein. TelyRxsecuritieshavenotbeen,andwillnotbe,reg isteredun dertheU.S.SecuritiesActof1933,asamended,andmaynotbeofferedorsoldinthe UnitedStatesabsentregistrationoranapplicableexemption.AnyofferingorsaleinCanadamustcomplywithapplicableCanadiansecuritieslaws.
Page 3
3 TelyRx delivers essential medication directly to you with no friction, no delays, and no excuses. The wait is over.
Page 4
4 Americans Better access for Access to 500+everyday medications, with less time, cost, and complexity. the majority of
Page 5
5 Your desired medication can be prescribed, dispensed, & shipped within 1 hour without you ever having to leave your house! From click to doorstep! Step 1 Step 2 Step 3 Choose your medication Independent providers prescribe TelyRx fulfills & delivers directly to you The average American waits days to access medication Driving to the doctor’s office Driving the prescription to the pharmacy Waiting for fulfillment Driving home from the pharmacy Submitting insurance claims Waiting In-person visit Scheduling delays
Page 6
6 Skip the waiting room Skip the pharmacy Skip insurance paperwork No appointments No memberships No insurance required $22 physician review fee Simple, seamless ordering Fast doorstep delivery What used to take days, now takes moments. Browse our formulary Request the prescription you need A licensed provider reviews your order and requests any additional information On approval, your medication is delivered quickly to you
Page 7
7 Categories* 8 Conditions 60+ Generic & branded drugs 500+ Access to everyday medications from our rapidly scaling, digital pharmacy platform *Chronic conditions, flu & infection, men’s and women’s health, skin and hair, digestive & travel, weight-loss & lifestyle Chronic Conditions Digestion Flu & Infection Weight-loss Men's Health Lifestyle Skin & Hair Women's Health 7% 4% 4%3% 3% 2% 2% 2% 2% 2% Ivermectin Zepbound Albuterol Tadalafil Mounjaro Azithromycin Ozempic Prednisone Tablets Estradiol Amoxicillin
Page 8
8 Physician Access Prescription Dispensing Logistics & Fulfillment TelyRx Insurance revenue prohibits providers from vertical integration1 Patients are choosing convenience & transparency Our 100% cash pay model permits vertical integration Most pharmacies are dependent on insurance revenue 1. Stark Law 42 U.S.C. § 1395nn; Anti-Kickback Statute 42 U.S.C. § 1320a-7b(b) Physician Access Prescription Dispensing Logistics & Fulfillment
Page 9
9 Out-of-pocket drug spend1 Cash-pay is a huge market opportunity Cash-pay segment has grown at CAGR240% 1. IQVIA: “Understanding the Use of Medicines in the U.S. 2025” 2. CAGR (2019-2024), data from www.pharmaceuticalcommerce.com, www.hmpglobal.com, and www.jrreport.wordandbrown.com TelyRx is capturing the fastest-growing segment of a massive market, one that traditional pharmacies legally cannot serve with a vertically integrated model $585B Total insured covered prescription market $98B
Page 10
10 The market has shifted. Behavior has changed Brick & mortar pharmacies are seeing declining margins ~2,300 pharmacies closed in 2024, with 15.8M Americans living in pharmacy deserts Traditional pharmacies are closing1 Federal law creates competitive hurdle Regulation creates defensible moat for vertically-integrated, cash-pay models, Amazon Pharmacy, CVS, Walgreens, prohibited from competing Alignment with telehealth and digital fulfillment trends where consumers value control and clarity in health care Permanently. Consumers are increasingly seeking alternatives outside traditional insurance 1. The Happy PharmD: “Pharmacy Closures in 2024”
Page 11
11 Engineered for National Scale with Minimal Capital Spend 250,000 2,850 99% 1. Currently not serving North Carolina or Arkansas Dallas, TX Opened January 2025, with first fulfillments May 2025 Clearwater, FL Opened January 2024 Two licensed pharmacies in Texas and Florida servicing ~97% of the U.S. population across 48 states & territories Our distribution facilities are near major airports to streamline shipping and logistics, reduce transit times, and lower costs Average prescriptions per day (Q2’26)
Page 12
12 Rapidly Scaling Patient & Revenue Growth with Strong Retention Metrics $1,172 $2,294 $3,596 $5,264 $7,874 $9,915 $12,660 $15,586 $1,712 $2,391 $3,335 $4,078 $4,462 $4,273 $6,734 $7,084 $458 $1,505 $2,884 $4,685 $6,931 $9,342 $12,337 $14,188 $19,394 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 New Customer Script RevenueRecurring Customer Script Revenue Revenue by New & Recurring Customers (in US$ 000s) New and recurring customer counts demonstrate strong retention while CAC2 remains within range 1. Compound Quarterly Growth Rate 2. Customer Acquisition Cost $22,670 +50% CQGR1
Page 13
13 Customer Unit Economics Strong Unit Economics: Profitable at Next Transaction 20% +12% +11% +16% +16% +10% +13% 0-7 8-14 15-21 22-30 31-45 46-60 61-90 Total Repeat Customers 59% Days Until New Customer's Second Purchase New Customer Day Count to Second Purchase 47% of new customers convert into repeat customers 59% of repeat customers make a second purchase within 30 days ~3.0 month payback $110Average order value 1. Based on financial data for 1H 2026 20% 32% 43% 75% 85% 98% 47% Average 1st Transaction1 Avg. Revenue $100 Gross Profit (57%) 57 Less: CAC (125) Less: Variable Pharmacy & Shipping Labor Costs (5) Net Loss $(73) 15% basket growth from 1st to 2nd transaction 1.22 avg purchases in-month Average Follow-on Transactions AOV 2nd transaction Purchases in month Avg Customer Value Avg. Revenue $115 1.22x $140 Gross Profit (57%) 80 Less: CAC - Less: Variable Pharmacy & Shipping Labor Costs (5) Net Profit $75
Page 14
14 Predictable Customer Revenues The LTR of $555 reflects the Q1‘24 cohort of customers measured as of June 30, 2026. Growth is driven by increased customer conversion supported by additional marketing investment.Quarterly cohorts exemplify predictable revenue growth 71,000 Compounded Quarterly Growth Rate for New Customers (Q1 2024 – Q2 2026) ↑42% New Customers in Q2 2026 Customer Lifetime Revenue by Quarter (US$/Customer) $555 1 2 3 4 5 6 7 8 9 10 Quarters Since First Purchase $100
Page 15
15 Improved Access Convenience Our Brand Promise Trust The TelyRx Marketing Plans & Strategies Cost Transparency
Page 16
16 Marketing Efficiency: Revenue Tracks to Traffic Growth $0.5 $1.5 $2.9 $4.7 $6.9 $9.3* $12.3 $14.3 $19.4 $22.7 0.5 0.9 0.8 1.3 1.4* 2.1 2.9 6.1 6.8 Q1'24 Q2'24 Q3'24 Q4'24 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Revenue (US$ Millions) Website Sessions (# Millions) *Launched website re-design during Q2’25, resulting in improved conversions. Subsequently, conversion improvements increased the effective revenue per visitor, thus higher revenue on lower website traffic. Website sessions growing nearly 20x from 0.3M to 6.8M quarterly (Q1‘24 to Q2‘26) In-house marketing advantage: Direct control over campaigns and faster optimization cycles position us for accelerated, capital-efficient growth
Page 17
17 Growing rapidly with focus on profitability Financials YE Dec. 31 (US$ in millions) Q2 2026 Q2 2025 2025 2024 Revenue $22.7 $9.3 $42.9 $9.5 Y/Y Growth 143% -- 352% -- Gross Profit $13.0 $5.1 $23.3 $3.5 Gross Profit % 57% 54% 54% 37% Operating Expenses* $18.5 $6.2 $25.2 $4.0 Adjusted EBITDA2 ($3.2) $(0.9) ($1.9) ($0.5) ▪ Revenue visibility through high customer retention rate ▪ Currently reinvesting gross margins into customer acquisition (4.4x LTR/CAC1 with 3- month payback validates this strategy) ▪ Highly discretionary capex and opex provides operating leverage *Adjusted for i) non-cash stock-based comp ii) RTO transaction fees, and iii) severance costs 1. LTR/CAC ratio based on the period ending lifetime revenue of the Q1'24 cohort of customers / the trailing 6 months averageCAC 2. Non-IFRS term. See Non-IFRS Measures disclaimer for more details. See the information under the heading “Non-IFRS Financial Measures” in the Management Discussion & Analysis of the Company for the period ended June 30, 2026 including in particular the reconciliation with IFRS measures, which information is incorporated herein by reference 3. Outstanding Subordinated Voting Shares including Preferred Voting Shares on as converted basis Capitalization Ticker TELY: TSX Share Price (08/07/2026 close) $2.70 SVS Shares 26,365,473 PVS Shares 224,967 Implied Shares Outstanding3 48,862,173 Implied Market Cap $131,927,867 Cash $21,675,000 Debt $10,200,000 Enterprise Value $120,452,867 Options Strike price (wt. avg.) $1.42 73,061 Warrants Strike price $2.19 26,113
Page 18
18 Competive Landscape D2C Telehealth + Integrated Pharmacy Pharmacy & Fulfillment Telehealth TelyRx has established itself as a unique competitor by being fully integrated & focusing on everyday, FDA approved, generic medicines Broad Offering Lifestyle Focused Digital Couriers Mail Order ✓ Cash pay focused ✓ Front end telehealth platform integrated in offering, allowing for customers to be prescribed by TelyRx & have prescription delivered • Cash pay focused, primarily subscription model • Front end telehealth platform integrated in offering, allowing for customers to be prescribed online & have prescription delivered • Lifestyle focused offering • Requires customers to obtain prescription separately via doctor's visit • App enabled service retrieving prescriptions from partner pharmacies • Insurance and cash-pay • Requires customers to obtain prescription separately via doctor's visit • Owns a licensed pharmacy that dispenses medications centrally and ships them via parcel carriers • Insurance pay focused • Provides consultation & healthcare services • Matches patients with doctors who can provide prescriptions • Do not deliver medications 60+ Conditions 450+ Medications Focused on a limited range of 4-5 lifestyle focused conditions
Page 19
19 Deeply Experienced & Dynamic Team Vanessa Slowey Chief Executive Officer Scaled operations across 27 markets $1.85B in exits Public company board governance John Cascio CPA Chief Financial Officer Big 4 financial rigor (PwC) Scaled multiple tech-enabled businesses, extensive PE-backed experience in growth & M&A $1.2B in exits Peter Lloyd Chief Revenue Officer Brand equity & commercial growth Digital marketing at scale Revenue growth across mobile, fibre & e-commerce Rafael Jose Chief Digital Officer Ad tech foundations (Google/Microsoft acquisitions) Scaled PE-backed digital brands P&L leadership Adam Gardner, PharmD Chief Operating Officer Pharmacist-in- Charge in 30+ states Tech-enabled pharmacy operations Big 4 financial controls $3.3B+ in exits Digital-first DNA Healthcare regulatory depth Brand & customer acquisition at scale E-commerce & DTC expertise
Page 20
20 Everyone needs medication. TelyRx delivers convenience. Unmatched Breadth: 450+ Medications Access to Our Proprietary Physician Network Zero Insurance Complexity True Vertical Integration Cash-pay Simplicity & Stark Law Competitive Moat Frictionless, Predictable, Fast Delivery
Page 21
21 There are a number of risk factors that could impact the Company’s ability to successfully execute its key strategies and may materially affect future events, performance or results. The risks and uncertainties described herein are not the only ones the Company may face. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also adversely affect the Company’s business. If any of the following or other risks occur, the business, prospects, financial condition, results of operations and cash flows of the Company could be materially adversely impacted. There is no assurance that risk management steps taken will avoid future loss due to the occurrence of the risks described below or other unforeseen risks. Risk factors relating to the Company include, but are not limited to, the factors set out below. Risk Factors • forward-looking information may prove inaccurate; • risk of inability to satisfy continuous listing requirements of the TSX; • increased price volatility of the Company’s shares; • significant sales of the Company’s shares could adversely affect share price; • the requirements of being a public issuer may strain the Company’s resources; • TelyRx has a limited operating history; • TelyRX has a history of losses and may never achieve profitability; • TelyRx has not paid dividends and does not anticipate paying dividends in the near future; • the Company may issue additional equity securities resulting in dilution; • the Company may require additional financing which may not be available; • risks related to potential conflicts of interest involving directors, officers and consultants; • TelyRx’s business model may be subject to legal challenges and regulatory actions; • TelyRx’s patient-directed medication request model may subject us to regulatory enforcement; • TelyRx’s clinical assessment methodology may be inadequate and result in liability claims; • risks related to patient safety and inappropriate prescribing due to limited clinical oversight; • TelyRx’s dependence on relationships with affiliated professional entities and risk of violating corporate practice of medicine laws; • TelyRx is subject to state-by-state regulatory compliance which creates operational complexity and costs; • TelyRx’s abbreviated clinical assessments may not comply with evolving telehealth regulations; • TelyRx’s clinical quality assurance capabilities may be inadequate; • TelyRx is subject to extensive healthcare, pharmacy, and telemedicine laws with risk of non-compliance; • TelyRx is subject to strict privacy and security laws, including HIPAA, with risk of data breaches; • risks related to dependence on maintaining and expanding a network of licensed physicians; • risks related to reliance on third parties and our own systems for providing services; • risks related to reliance on third-party technology providers and infrastructure; • risks related to reliance on third-party logistics providers to deliver medications; • risks related to prescription fulfillment errors or disruption; • risks related to products subject to Food and Drug Administration regulations and other state and local requirements • TelyRx’s history of cumulative losses and uncertainty regarding profitability; • risks related to fluctuations in shipping costs, labor costs, or drug acquisition prices; • TelyRx is operating in highly competitive markets; • TelyRx’s dependence on growth strategy and strategic relationships with third parties; • TelyRx may not grow at historical rates or at all, which could have a material adverse effect on the market price of our shares; • risks related to heavy reliance on third-party advertising platforms for patient acquisition; • risks related to marketing practices subject to extensive regulations including Federal Trade Commission and Food and Drug Administration; • risks related to marketing reliance on sensitive healthcare content and third-party influencers; • risks related to rapid technological change in the telemedicine market; • dependence on ability to recruit, retain and develop qualified workforce and service providers; • TelyRx operates in the healthcare industry which is highly sensitive to reputational risk; • risks related to promoting products for unapproved uses; • risks related to losses or liability not covered by insurance; • risks related to costly and time-consuming litigation; • risks related to failure to protect or enforce intellectual property rights; • risks related to claims that TelyRx violated intellectual property rights of others; • risks related to natural or man-made disasters and other similar events; • risks related to significant inventory of TelyRx being stored in limited facilities; • TelyRx‘s dependence on patients’ ability to access the internet; • risks related to the TelyRx’s potential international expansion; • economic uncertainty or downturns could adversely affect TelyRx; • TelyRx is a Foreign Private Issuer for U.S. securities law purposes but may lose this status; • the loss of Foreign Private Issuer status may have adverse consequences; • risks related to the enforceability of judgments against foreign subsidiaries; • conversion limitations on our shares will limit liquidity.
Page 22
22 TSX: TELY | OTCQX: TELYF